— ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q4 2019 loss of $0.34 per share, vs. $0.36 expected.
— Revenue grew 65% to $98.3 million vs. $97.76 million expected.
— For FY20, NUPLAZID sales is expected to be between $440 million and $470 million.
— For fiscal 2020, GAAP R&D expense is expected to be between $270 and $285 million and GAAP SG&A expense is expected to be between $440 and $460 million.
— ACAD shares rose about 4% following the earnings announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event
Most Popular
GIS Earnings: All you need to know about General Mills’ Q1 2025 earnings results
General Mills, Inc. (NYSE: GIS) reported its first quarter 2025 earnings results today. Net sales decreased 1% year-over-year to $4.8 billion. Organic sales were down 1%. Net earnings attributable to
Guardian Pharmacy seeks to raise up to $108 mil in US IPO
Joining the wave of healthcare IPOs this year, amid Fed rate cut expectations, Guardian Pharmacy Services, Inc. is preparing to go public. In a statement filed with the Securities and
Earnings Preview: Will Micron (MU) maintain recovery momentum in Q4?
After recovering from a rough patch, Micron Technology Inc. (NASDAQ: MU) is preparing to report fourth-quarter results next week, even as the market keeps a close watch on the event
